NCT03587038View on ClinicalTrials.gov

OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

September 3, 2018

Primary Completion Date

December 23, 2020

Study Completion Date

November 30, 2026

Conditions
Glioblastoma
Interventions
DRUG

OKN 007

400 mg OKN-007/mL in a phosphate buffer

DRUG

Temozolomide

75 mg/m2

RADIATION

Photon/Proton IMRT

standard of care treatment to be given 1 to 2 hours after OKN-007

Trial Locations (1)

73117

Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City

All Listed Sponsors
lead

University of Oklahoma

OTHER